Do major cardiovascular outcomes in patients with stable ischemic heart disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial differ by healthcare system?

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 5, 2010, Pages 476-483

  Chaitman, Bernard R ^a   Hartigan, Pamela M ^b   Booth, David C ^c   Teo, Koon K ^d   Mancini, John ^e   Kostuk, William J ^f   Spertus, John A ^g   Maron, David J ^h   Dada, Marcin ⁱ   O'Rourke, Robert A ^j   Weintraub, William S ^k   Berman, Daniel S ^l   Shaw, Leslee J ^m   Boden, William E ⁿ  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ HARTFORD HOSPITAL   (United States)

^j SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^k CHRISTIANA CARE HEALTH SYSTEM   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m EMORY UNIVERSITY   (United States)

ⁿ UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

Angina pectoris; Angioplasty; Coronary disease; Follow up studies; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG SCREENING; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE SYSTEM; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORTH AMERICA; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CANADA; COMORBIDITY; DELIVERY OF HEALTH CARE; DISEASE PROGRESSION; DRUG THERAPY; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT; VETERANS;

EID: 78650202240     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.901579     Document Type: Article

References (33)

1. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris C, Chaitman BR, Shaw L, Gosselin G, Nawaz Sh, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
2. Frye RL, August P, Brooks M, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TLZ, Molitch ME, Nesto RW, Sako EY, Sobel BE; BARI IID Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
3. Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GBJ, Weintraub WS; COURAGE Trial Investigators. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end-points in patients with stable coronary artery disease (from the COURAGE trial). Am J Cardiol. 2009;104:1-4.
4. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG; Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
5. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini J, Berman DS, Gau G, Weintraub WS; COURAGE Trial Co-principal Investigators and Study Coordinators. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2007;99:208-212.
6. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GBJ, Berman DS, Weintraub WS; COURAGE Trial Coinvestigators and Study Coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006;151:1173-1179.
7. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333-341.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Schoenfeld DA, Tsiatis AA. A modified log rank test for highly stratified data. Biometrika. 1987;74:167-175.
10. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
11. Little RJA, Rubin DB. Statistical Analysis with Missing Data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002.
12. Mancini GBJ, Bates ER, Maron DJ, Hartigan P, Dada M, Gosselin G, Kostuk W, Sedlis SP, Shaw LJ, Berman DS, Berger PB, Spertus J, Mavromatis K, Knudtson M, Chaitman BR, O'Rourke RA, Weintraub WS, Teo K, Boden WE; COURAGE Trial Investigators and Coordinators. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. Circ Cardiovasc Qual Outcomes 2009;2:320-327.
13. Kaul P, Armstrong PW, Chang WC, Naylor D, Granger CB, Lee KL, Peterson ED, Califf RM, Topol EJ, Mark DB. Long-term mortality of patients with acute myocardial infarction in the United States and Canada. Comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Circulation. 2004;110:1754-1760.
14. Ko DT, Krumholz HM, Wang Y, Foody JM, Masoudi FA, Havranek EP, You JJ, Alter DA, Stukel TA, Newman AM, Tu JV. Regional differences in process of care and outcomes for older acute myocardial infarction patients in the United States and Ontario, Canada Circulation. 2007;115:196-203.
15. Birnie DH, Sambell C, Johansen H, Williams K, Lemery R, Green MS, Gollob MH, Lee DS, Tang ASL. Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. CMAJ. 2007;177:41-46.
16. Rouleau JL, Moye LA, Pfeffer MA, Arnold JMO, Bernstein V, Cuddy TE, Dagenais GR, Geltman EM, Goldman S, Gordon D, Hamm P, Klein M, Lamas, McCans J, McEwan P, Menapace FJ, Parker JO, Sestier F, Sussex B, Braunwald E; SAVE Investigators. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med. 1993;328:779-784.
17. Bourassa MG, Brooks MM, Mark DB, Trudel J, Detre KM, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Smith HC, Whitlow PL, Wiens RD, Hlatky MA. Quality of life after coronary revascularization in the United States and Canada. Am J Cardiol. 2000;85:548-553.
18. Pilote L, Merrett P, Karp I, Alter D, Austin PC, Cox J, Johansen H, Ghali W, Tu JV. Cardiac procedures after an acute myocardial infarction across nine Canadian provinces. Can J Cardiol. 2004;20:491-500.
19. Ko DT, Tu JV, Masoudi FA, Wang Y, Havranek DP, Rathore SS, Newman AM, Donovan LR, Lee DS, Foody JM, Krumholz HM. Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada. Arch Intern Med. 2005;165:2486-2492. (Pubitemid 41720010)
20. Sanmartin C, Berthelot JM, Ng E, Murphy K, Blackwell DL, Gentleman JF, Martinez ME, Simile CMl. Comparing health and health care use in Canada and the United States. Health Affairs. 2006;25:1133-1142.
21. Kaul P, Newby LK, FU Y, Wagner GS, Harrington RA, Granger CB, Van de Werf F, Ohman EM, Armstrong PW; VIGOUR Group. Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns. Heart. 2005;91:876-881.
22. Lasser KE, Himmelstein DU, Woolhandler S. Access to care, health status, and health disparities in the United States and Canada: Results of a cross-national population-based survey. Am J Public Health. 2006;96:1300-1307.
23. Petersen LA, Normand SLT, Leape LL, McNeil BJ. Regionalization and underuse of angiography in the Veterans Affairs health care system as compared with a fee-for-service system. N Engl J Med. 2003;348:2209-2217.
24. Petersen LA, Normand SLT, Daley J, McNeil BJ. Outcome of myocardial infarction in Veterans Health Administration patients as compared with Medicare patients. N Engl J Med. 2000;343:1934-1941.
25. Loeb HS. Use of angiography in the Veterans Affairs health care system and Medicare. N Engl J Med. 2003;349:1093.
26. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
27. Katritsis DG, Ioannidis JPA. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005;111:2906-2912.
28. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911-918.
29. Maron DJ, Spertus JA, Mancini J, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE; COURAGE Trial Research Group. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. Am J Cardiol. 2009;104:1055-1062.
30. Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GBJ, Weintraub WS; COURAGE Trial Investigators. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease. J Am Coll Cardiol. 2009;54:1303-1308.
31. Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GBJ, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. J Am Coll Cardiol. 2010;55:1348-1358.
32. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King S, Frye RL; BARI 2D Study Group. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). Am J Cardiol. 2009;103:632-638.
33. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease. Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529-2540.